Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Use of partial area under the curve metrics to assess bioequivalence of methylphenidate multiphasic modified release formulations.

Stier EM, Davit BM, Chandaroy P, Chen ML, Fourie-Zirkelbach J, Jackson A, Kim S, Lionberger R, Mehta M, Uppoor RS, Wang Y, Yu L, Conner DP.

AAPS J. 2012 Dec;14(4):925-6. doi: 10.1208/s12248-012-9397-7. Epub 2012 Sep 14. No abstract available.

2.
3.

Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria.

Shram MJ, Quinn AM, Chen N, Faulknor J, Luong D, Sellers EM, Endrenyi L.

Clin Ther. 2012 May;34(5):1170-81. doi: 10.1016/j.clinthera.2012.02.010. Epub 2012 Apr 17.

PMID:
22512898
4.

Lack of bioequivalence between two methylphenidate extended modified release formulations in healthy volunteers.

Schütz H, Fischer R, Grossmann M, Mazur D, Leis HJ, Ammer R.

Int J Clin Pharmacol Ther. 2009 Dec;47(12):761-9.

PMID:
19954715
5.

Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.

Markowitz JS, Straughn AB, Patrick KS, DeVane CL, Pestreich L, Lee J, Wang Y, Muniz R.

Clin Pharmacokinet. 2003;42(4):393-401.

PMID:
12648029
6.

A pharmacokinetic study of two modified-release methylphenidate formulations under different food conditions in healthy volunteers.

Haessler F, Tracik F, Dietrich H, Stammer H, Klatt J.

Int J Clin Pharmacol Ther. 2008 Sep;46(9):466-76.

PMID:
18793577
7.

Bioequivalence of a methylphenidate hydrochloride extended-release preparation: comparison of an intact capsule and an opened capsule sprinkled on applesauce.

Fischer R, Schütz H, Grossmann M, Leis HJ, Ammer R.

Int J Clin Pharmacol Ther. 2006 Mar;44(3):135-41.

PMID:
16550736
8.

Flawed attention-deficit/hyperactivity disorder medication comparison.

Adesman A.

Pediatrics. 2004 Oct;114(4):1132; author reply 1132-3. No abstract available.

PMID:
15466129
9.

In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.

Wang Y, Lee L, Somma R, Thompson G, Bakhtiar R, Lee J, Rekhi GS, Lau H, Sedek G, Hossain M.

Biopharm Drug Dispos. 2004 Mar;25(2):91-8.

PMID:
14872557
10.

Comments on effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR food evaluation study.

González MA, Polli JE, Morgan JA.

Curr Med Res Opin. 2002;18(7):vii-x. No abstract available.

PMID:
12487510
11.

The need for additional metrics to assess therapeutic equivalence of some multiphasic modified-release products.

Kondra PM, Endrenyi L, Tothfalusi L.

Clin Ther. 2011 Sep;33(9):1214-9. doi: 10.1016/j.clinthera.2011.07.014. Epub 2011 Aug 17.

PMID:
21849209
12.
13.

Use of partial AUC (PAUC) to evaluate bioequivalence--a case study with complex absorption: methylphenidate.

Fourie Zirkelbach J, Jackson AJ, Wang Y, Schuirmann DJ.

Pharm Res. 2013 Jan;30(1):191-202. doi: 10.1007/s11095-012-0862-x. Epub 2012 Sep 25.

PMID:
23007665
14.

Dose-proportional pharmacokinetics of a methylphenidate extended-release capsule.

Rochdi M, González MA, Dirksen SJ.

Int J Clin Pharmacol Ther. 2004 May;42(5):285-92.

PMID:
15176652
15.

Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man.

Tuerck D, Wang Y, Maboudian M, Wang Y, Sedek G, Pommier F, Appel-Dingemanse S.

Int J Clin Pharmacol Ther. 2007 Dec;45(12):662-8.

PMID:
18184535
16.
17.

Pharmacokinetics of methylphenidate after oral administration of immediate and sustained-release preparations in Beagle dogs.

Lavy E, Prise U, Soldani G, Neri D, Brandriss N, Bar Chaim A, Giorgi M.

Vet J. 2011 Sep;189(3):336-40. doi: 10.1016/j.tvjl.2010.07.007. Epub 2010 Aug 8.

PMID:
20696604
18.

A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ; COMACS Study Group.

Pediatrics. 2004 Mar;113(3 Pt 1):e206-16.

PMID:
14993578
19.

Single-dose pharmacokinetics of multilayer-release methylphenidate and immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.

Quinn D, Bode T, Reiz JL, Donnelly GA, Darke AC.

J Clin Pharmacol. 2007 Jun;47(6):760-6. Epub 2007 Mar 29.

PMID:
17395894
20.

Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered sprinkled on food or as an intact capsule.

Pentikis HS, Simmons RD, Benedict MF, Hatch SJ.

J Am Acad Child Adolesc Psychiatry. 2002 Apr;41(4):443-9.

PMID:
11931601
Items per page

Supplemental Content

Write to the Help Desk